Xvivo Perfusion AB (publ) (0RKL.L)
- Previous Close
354.75 - Open
369.00 - Bid --
- Ask --
- Day's Range
361.50 - 376.50 - 52 Week Range
205.50 - 376.50 - Volume
3,198 - Avg. Volume
9,843 - Market Cap (intraday)
98.817M - Beta (5Y Monthly) 2.09
- PE Ratio (TTM)
15.74 - EPS (TTM)
0.24 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.
www.xvivogroup.com148
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0RKL.L
Performance Overview: 0RKL.L
Trailing total returns as of 4/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0RKL.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0RKL.L
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
15.62%
Return on Assets (ttm)
0.41%
Return on Equity (ttm)
5.82%
Revenue (ttm)
642.95M
Net Income Avi to Common (ttm)
100.43M
Diluted EPS (ttm)
0.24
Balance Sheet and Cash Flow
Total Cash (mrq)
511.15M
Total Debt/Equity (mrq)
1.54%
Levered Free Cash Flow (ttm)
-90.84M
Company Insights: 0RKL.L
0RKL.L does not have Company Insights